213 related articles for article (PubMed ID: 24613363)
1. Synergistic interaction between genetics and disease on pravastatin disposition.
Clarke JD; Hardwick RN; Lake AD; Lickteig AJ; Goedken MJ; Klaassen CD; Cherrington NJ
J Hepatol; 2014 Jul; 61(1):139-47. PubMed ID: 24613363
[TBL] [Abstract][Full Text] [Related]
2. Interaction of Oatp1b2 expression and nonalcoholic steatohepatitis on pravastatin plasma clearance.
Toth EL; Clarke JD; Csanaky IL; Cherrington NJ
Biochem Pharmacol; 2020 Apr; 174():113780. PubMed ID: 31881192
[TBL] [Abstract][Full Text] [Related]
3. Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin.
Zaher H; Meyer zu Schwabedissen HE; Tirona RG; Cox ML; Obert LA; Agrawal N; Palandra J; Stock JL; Kim RB; Ware JA
Mol Pharmacol; 2008 Aug; 74(2):320-9. PubMed ID: 18413659
[TBL] [Abstract][Full Text] [Related]
4. Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression.
Clarke JD; Hardwick RN; Lake AD; Canet MJ; Cherrington NJ
J Pharmacol Exp Ther; 2014 Mar; 348(3):452-8. PubMed ID: 24403518
[TBL] [Abstract][Full Text] [Related]
5. Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein.
Higgins JW; Bao JQ; Ke AB; Manro JR; Fallon JK; Smith PC; Zamek-Gliszczynski MJ
Drug Metab Dispos; 2014 Jan; 42(1):182-92. PubMed ID: 24194513
[TBL] [Abstract][Full Text] [Related]
6. Contribution of hepatic organic anion-transporting polypeptides to docetaxel uptake and clearance.
Lee HH; Leake BF; Teft W; Tirona RG; Kim RB; Ho RH
Mol Cancer Ther; 2015 Apr; 14(4):994-1003. PubMed ID: 25695959
[TBL] [Abstract][Full Text] [Related]
7. Evodiamine decreased the systemic exposure of pravastatin in non-alcoholic steatohepatitis rats due to the up-regulation of hepatic OATPs.
Liang R; Ge W; Li B; Cui W; Ma X; Pan Y; Li G
Pharm Biol; 2022 Dec; 60(1):359-373. PubMed ID: 35171063
[TBL] [Abstract][Full Text] [Related]
8. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril.
Maeda K; Ieiri I; Yasuda K; Fujino A; Fujiwara H; Otsubo K; Hirano M; Watanabe T; Kitamura Y; Kusuhara H; Sugiyama Y
Clin Pharmacol Ther; 2006 May; 79(5):427-39. PubMed ID: 16678545
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics.
Nishizato Y; Ieiri I; Suzuki H; Kimura M; Kawabata K; Hirota T; Takane H; Irie S; Kusuhara H; Urasaki Y; Urae A; Higuchi S; Otsubo K; Sugiyama Y
Clin Pharmacol Ther; 2003 Jun; 73(6):554-65. PubMed ID: 12811365
[TBL] [Abstract][Full Text] [Related]
10. Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport.
Kindla J; Müller F; Mieth M; Fromm MF; König J
Drug Metab Dispos; 2011 Jun; 39(6):1047-53. PubMed ID: 21389119
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic Effects of Different Models of Nonalcoholic Fatty Liver Disease in Transgenic Humanized OATP1B Mice.
Bechtold BJ; Lynch KD; Oyanna VO; Call MR; White LA; Graf TN; Oberlies NH; Clarke JD
Drug Metab Dispos; 2024 Apr; 52(5):355-367. PubMed ID: 38485280
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of organic anion transporting polypeptide 1B1 and 1B3 humanized mice as a translational model to study the pharmacokinetics of statins.
Salphati L; Chu X; Chen L; Prasad B; Dallas S; Evers R; Mamaril-Fishman D; Geier EG; Kehler J; Kunta J; Mezler M; Laplanche L; Pang J; Rode A; Soars MG; Unadkat JD; van Waterschoot RA; Yabut J; Schinkel AH; Scheer N
Drug Metab Dispos; 2014 Aug; 42(8):1301-13. PubMed ID: 24855184
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.
Ieiri I; Higuchi S; Sugiyama Y
Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):703-29. PubMed ID: 19442037
[TBL] [Abstract][Full Text] [Related]
14. The role of hepatic transport and metabolism in the interactions between pravastatin or repaglinide and two rOatp inhibitors in rats.
Badolo L; Bundgaard C; Garmer M; Jensen B
Eur J Pharm Sci; 2013 Jul; 49(4):767-72. PubMed ID: 23648783
[TBL] [Abstract][Full Text] [Related]
15. Prediction of the Pharmacokinetics of Pravastatin as an OATP Substrate Using Plateable Human Hepatocytes With Human Plasma Data and PBPK Modeling.
Mao J; Doshi U; Wright M; Hop CECA; Li AP; Chen Y
CPT Pharmacometrics Syst Pharmacol; 2018 Apr; 7(4):251-258. PubMed ID: 29388346
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the organic anion-transporting polypeptide 1B1 by quercetin: an in vitro and in vivo assessment.
Wu LX; Guo CX; Chen WQ; Yu J; Qu Q; Chen Y; Tan ZR; Wang G; Fan L; Li Q; Zhang W; Zhou HH
Br J Clin Pharmacol; 2012 May; 73(5):750-7. PubMed ID: 22114872
[TBL] [Abstract][Full Text] [Related]
17. Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1).
van de Steeg E; van der Kruijssen CM; Wagenaar E; Burggraaff JE; Mesman E; Kenworthy KE; Schinkel AH
Drug Metab Dispos; 2009 Feb; 37(2):277-81. PubMed ID: 19022939
[TBL] [Abstract][Full Text] [Related]
18. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.
Kivistö KT; Niemi M
Pharm Res; 2007 Feb; 24(2):239-47. PubMed ID: 17177112
[TBL] [Abstract][Full Text] [Related]
19. Rifampin- and Silymarin-Mediated Pharmacokinetic Interactions of Exogenous and Endogenous Substrates in a Transgenic OATP1B Mouse Model.
Bechtold BJ; Lynch KD; Oyanna VO; Call MR; Graf TN; Oberlies NH; Clarke JD
Mol Pharm; 2024 May; 21(5):2284-2297. PubMed ID: 38529622
[TBL] [Abstract][Full Text] [Related]
20. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3.
Noé J; Portmann R; Brun ME; Funk C
Drug Metab Dispos; 2007 Aug; 35(8):1308-14. PubMed ID: 17470528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
